[{"Assets_0_Q2_USD":1858284000.0,"CommonStockSharesOutstanding_0_Q2_shares":21095174.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":134405000.0,"NetIncomeLoss_1_Q2_USD":73160000.0,"NetIncomeLoss_2_Q2_USD":118441000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":24437922.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":24618249.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":21212000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":21209000.0,"StockholdersEquity_0_Q2_USD":619813000.0,"EarningsPerShareBasic_1_Q2_USD":3.45,"EarningsPerShareBasic_2_Q2_USD":5.58,"EarningsPerShareDiluted_1_Q2_USD":2.99,"EarningsPerShareDiluted_2_Q2_USD":4.81,"Ticker":"LGND","CIK":"886163","name":"LIGAND PHARMACEUTICALS INC","OfficialName":"Ligand Pharmaceuticals Incorporated Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1738856427.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20180808"}]